Development of an HbA1c-Based Conversion Equation for Estimating Glycated Albumin in a Korean Population with a Wide Range of Glucose Intolerance

Chang Hee Jung1*, You-Cheol Hwang2*, Kwang Joon Kim3, Bong Soo Cha3, Cheol-Young Park4, Won Seon Jeon4, Jae Hyeon Kim4, Sang-Man Jin5, Sang Youl Rhee2, Jeong-taek Woo2*, Byung-Wan Lee3*

1 Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, 2 Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea, 3 Department of Internal Medicine, Severance Hospital, University of Yonsei University College of Medicine, Seoul, Korea, 4 Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, 5 Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Abstract

Background: Compared to the golden standard glycation index of HbA1c, glycated albumin (GA) has potentials for assessing insulin secretory dysfunction and glycemic fluctuation as well as predicting diabetic vascular complications. Therefore, a conversion equation for HbA1c and GA would help physician for managing patients with diabetes, although it remains to be clarified. We designed this study to determine the reference ranges in patients with normal glucose tolerance (NGT) based on conventional measures of glycemic status and to devise a conversion equation for calculating HbA1c and GA in a Korean population.

Methodology/Principal Findings: In this multicenter, retrospective, cross-sectional study, we recruited antidiabetic drug-naïve patients with available glycemic variables including HbA1c, GA, and fasting plasma glucose regardless of glucose status. For the reference interval of serum GA, 5th to 95th percentile value of GA in subjects with NGT was adopted. The conversion equation between HbA1c and GA was devised using an estimating regression model with unknown breakpoint method. The reference range for GA was 9.0–14.0% in 2043 subjects. The 95th percentile responding values for FPG, and HbA1c were approximately 5.49 mmol/l, and 5.6%, respectively. The significant glycemic turning points were 5.868% HbA1c and 12.2% GA. The proposed conversion equation for below and above the turning point were GA (%) = 6.960 × HbA1c (%), and HbA1c (%) = −9.609 + 3.720 × GA (%), respectively.

Conclusions/Significance: These results should be helpful in future studies on the clinical implications of high GA relative to HbA1c and the clinical implementation of diabetes management.

Introduction

Currently, HbA1c is the golden standard glycation index for use in clinical practice and research [1]. However, it can be unreliable in conditions affecting the lifespan of erythrocytes as well as the clinical state in which glycemic control alleviates or deteriorates in the short period. By overcoming the shortcomings of HbA1c, glycated albumin (GA) has gained popularity as an useful index for intermediate glycation and pathogenic protein [2].

Besides the role of GA as an intermediate glycation index, several previous studies have suggested additional values of GA in reference to HbA1c levels in assessing insulin secretory dysfunction and fluctuating glycemic excursions [2–4]. Furthermore, elevated serum GA levels as well as GA/HbA1c ratio have been suggested to predict diabetic macrovascular complications [3]. Therefore, a simple and accurate conversion equation determining GA using HbA1c (and vice versa) would help physician for managing patients with diabetes, although it remains to be clarified. Previously, an easy but rough approximation (i.e., HbA1c = GA/0.8963) has been suggested [6]. However, GA levels are at unexpectedly high levels, over HbA1c in patients with long duration of diabetes or decreased insulin secretory function. Hence, this equation was not acceptable for empirical adoption and lacked statistical significance [7]. In addition, a similar but different concept of the GA/HbA1c ratio conferred additional clinical implications regarding glucometabolic homeostasis and diabetic atherosclerosis rather than simply converting GA to HbA1c [2,3,5].

Based on a previous study, where GA reportedly increased by 2.5–3.2% for every 1% increase in serum HbA1c (range: 6.5–14.0% HbA1c) [4], we hypothesized that the proportion of HbA1c to GA would differ in prediabetic and diabetic patients depending on their glycemic status such as normal glucose tolerance (NGT), pre-diabetes and type 2 diabetes (T2D). In this multicenter cross-sectional study, our aims are to determine the reference ranges in...
patients with NGT based on conventional measures of glycemic status [8,9], and devise a conversion equation for calculating HbA1c and GA in a Korean population.

Materials and Methods

Ethics Statement
This study was approved by the independent ethics committee/ institutional review board (IRB) at each study site [IRB of Severance Hospital Yonsei University College of Medicine, Asian Medical Center, University of Ulsan College of Medicine, Kyunghee University Hospital, Kyunghee University Hospital at Gangdong, Kangbuk Samsung Medical Center, Sungkyunkwan University School of Medicine, and Samsung Medical Center, Sungkyunkwan University School of Medicine, respectively]. All enrolled subjects provided written informed consent.

Study Population
Study subjects were recruited from outpatient clinics at 6 major referral centers; a total of 2450 patients who were registered with the health check-up program of Severance Hospital or the Newly Detected Diabetes Registry in Asan Medical Center, Kyunghee Hospital, Kangdong Kyunghee Hospital, Kangbuk Samsung Hospital, Samsung Medical Center, and Severance Hospital were recruited. All patients had their GA, HbA1c, and fasting plasma glucose (FPG) levels measured. All study participants had fasting C-peptide levels of >0.5 ng/mL. We excluded patients without GA, HbA1c, or FPG data and those with any of the following criteria that might affect GA or HbA1c: hemoglobin (Hb) level <12 g/dL for women and <13 g/dL for men; chronic kidney disease stage 3 (i.e., estimated glomerular filtration rate [eGFR] <60 mL/minute/1.73 m² according to the Modification of Diet in Renal Disease criteria [MDRD]); active thyroid disease; liver cirrhosis; or nephrotic syndrome.

Clinical and Laboratory Examination
The body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. All blood samples were obtained in the morning, following an overnight fasting of at least 12 hours. Plasma glucose was measured by the hexokinase method. Lípid parameters, including serum total cholesterol, triglycerides, HDL cholesterol (HDL-C), directly-measured LDL cholesterol (LDL-C) levels, and liver enzymes, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT), were measured using an enzymatic colorimetric method. Serum GA was determined by an enzymatic method using an albumin-specific proteinase, ketoamine oxidase and albumin assay reagent (LUCICA GA-I, Asahi Kasei Pharma Co., Tokyo, Japan), and a Hitachi 7600 Pmodule autoanalyzer (Hitachi Instruments Service, Tokyo, Japan). The coefficient of variation (CV) was 1.43%. HbA1c was measured by high-performance liquid chromatography (HPLC) method. The reference intervals of HbA1c were between 4.0% and 6.0%. HOMA of insulin resistance (HOMA-IR) was calculated as the product of fasting serum insulin (μU/ml) and FPG (mmol/l) concentrations, divided by 22.5. HOMA of beta cell function (HOMA-beta) was calculated according to the equation: HOMA-beta (%) = (20 × fasting serum insulin)/(FPG-3.5). All enzyme activities were measured at 37°C.

In this study, NGT was defined by the previously defined criteria [8,9]: (1) FPG <5.55 mmol/l and (2) HbA1c <5.7%.

Statistical Methods
Continuous variables are expressed as the mean ± standard deviation [SD]. Categorical variables are expressed as proportions (%). Demographic and biochemical characteristics of the study population between the two arbitrarily defined groups in this study were compared using independent t-test for continuous variables and the chi-squared test for categorical variables. To determine the relationship between serum GA and HbA1c levels according to the deterioration of glucose tolerance, we performed the estimating regression model with unknown break-points as previously described [10]. The normal reference interval of serum GA was determined directly from the percentage of interest (i.e., the 5–95th percentile of patients with NGT). The relationship between glycemic parameters including FPG, GA, and HbA1c were calculated using linear regression analysis after assigning HbA1c and GA as dependent variables and FPG as independent variables. R version 2.14.0 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org) was used to analyze the data. All p-values <0.05 were considered statistically significant.

Results
A total of 2043 subjects out of all that were recruited satisfied the inclusion and exclusion criteria of this study. The clinical characteristics of the study participants are shown in Table 1. The mean age of the study subjects was 54.1±11.1 years with relatively even gender distribution (57.5% male). The mean BMI was 25.0±3.3 kg/m². When we fitted estimating regression models with unknown break-points, serum GA levels were drastically increased from HbA1C level of 5.868% (Fig. 1). Based on this turning point of the slope, we classified the subjects into two groups [group I, HbA1c <5.9% (n=736); group II, HbA1c ≥5.9% (n=1307)]. The subjects in group II were statistically older (50.9±10.4 vs. 56.0±11.0 years in group I and group II, respectively; p<0.001) and more obese (24.2±3.2 vs. 25.4±3.2 kg/m² in years in group I and group II, respectively; p<0.001). The Hb concentration were similar between the two groups (14.6±1.2 vs. 14.6±1.3 g/dL in years in group I and group II, respectively; p=0.949). Similar to our previous reports [3,4], serum albumin levels were different between the two groups (4.5±0.4 vs. 4.4±0.3 mg/dL in group I and group II, respectively; p<0.001). The percentage of current smoker was similar (22.8% vs. 21.0% in group I and group II, respectively; p=0.391), but the blood pressure and glucometabolic profiles, including FPG, GA, HOMA-IR, and HOMA-β, were significantly higher in group II. Finally, significantly more patients in group II were taking antihypertensive and antilipid medications.

Table 2 shows the selected percentile concentrations for FPG, GA, and HbA1c in patients with NGT. The 25–75th percentile interval value was approximately 11.0–12.3% for GA, while the 5–95th percentile interval was approximately 9.0–14.0% in patients with NGT. In this study, the 5th percentile values for FPG, GA, and HbA1c were approximately 99 mg/dL, 14.0%, and 3.6%, respectively. The FPG and HbA1c values, according to the individual percentile points, were almost exactly same between sexes; but, the GA values were similar.

Table 2 shows the overall correlations between HbA1c and GA (Fig. 2A), FPG and HbA1c (Fig. 2B), and FPG and GA (Fig. 2C). The positive correlation coefficient between HbA1c and GA was the highest (r=0.915; p<0.001; Fig. 2A). Furthermore, FPG
concentrations demonstrated significant positive correlations to both HbA1c ($r = 0.821; p < 0.001$, Fig. 2B) and GA ($r = 0.817; p < 0.001$, Fig. 2C). Similar to previous studies [3,4], our results indicated that FPG demonstrated a stronger correlation with HbA1c over GA. The HbA1c and GA levels corresponding to FPG were 5.9% and 12.6% for 5.55 mmol/l FPG, 6.3% and 14.0% for 6.11 mmol/l, and 6.8% and 16.0% for 6.94 mmol/l, respectively.

Figure 1 shows the significant glycemic turning point, which demonstrates an apparently linear trend above and below the turning point from normal glucose to high glucose status. As previously mentioned, we divided the patients into two groups based on this turning point. Below and above 5.868% HbA1c, the conversion equations obtained using the estimating regression models with unknown breakpoints [10] for group I (HbA1c < 5.868%) and group II (HbA1c ≥ 5.868%) were GA (%) = 6.960 + 0.8963 × HbA1c (%) and GA (%) = −9.609 + 3.720 × HbA1c (%), respectively. The positive correlation coefficients for HbA1c and GA were 0.135 ($p < 0.001$) and 0.912 ($p < 0.001$) for groups I and II, respectively.

In table 3, the mean values of GA, GA/HbA1c ratio, and FPG were analyzed according to the levels of HbA1c, which is the standard glycation index used in clinical practice and research. Based on the result regarding the turning point of 5.9% HbA1c in the continuous plots of GA and HbA1c (Fig. 1),

**Table 1. Clinical and biochemical characteristics of the study participants.**

| Variables                  | Total (n = 2043) | Group I (G1) (n = 736) | Group II (GII) (n = 1307) | GS vs. GSII $P$ value |
|----------------------------|------------------|------------------------|---------------------------|----------------------|
| Male (n, %)                | 1175 (57.5)      | 395 (53.7)             | 780 (59.7)                | 0.009                |
| Age (years)                | 54.1 (11.1)      | 50.9 (10.4)            | 56.0 (11.0)               | <0.001               |
| BMI (kg/m$^2$)             | 25.0 (3.3)       | 24.2 (3.2)             | 25.4 (3.2)                | <0.001               |
| WC (cm)                    | 85.5 (8.9)       | 83.2 (8.7)             | 87.1 (8.6)                | <0.001               |
| Systolic BP (mmHg)         | 126.5 (16.4)     | 121.6 (15.1)           | 129.2 (16.4)              | <0.001               |
| Diastolic BP (mmHg)        | 78.0 (11.0)      | 76.2 (10.4)            | 78.9 (11.1)               | <0.001               |
| Current smoker (%)         | 17.0             | 22.8                   | 21.0                      | 0.391                |
| Anti-HTN medication (%)    | 23.7             | 18.7                   | 32.0                      | <0.001               |
| Anti-lipid medication (%)  | 14.2             | 15.0                   | 21.1                      | 0.002                |
| FPG (mmol/l)               | 6.67 (2.09)      | 5.58 (0.67)            | 7.29 (2.36)               | <0.001               |
| HbA1c (%)                  | 6.6 (1.6)        | 5.5 (0.2)              | 7.3 (1.7)                 | <0.001               |
| GA (%)                     | 15.4 (6.3)       | 11.9 (1.5)             | 17.4 (7.0)                | <0.001               |
| Hb (g/dl)                  | 14.6 (1.3)       | 14.6 (1.2)             | 14.6 (1.3)                | 0.949                |
| Protein (g/l)              | 7.1 (0.4)        | 7.0 (0.4)              | 7.1 (0.4)                 | 0.001                |
| Albumin (g/l)              | 4.5 (0.4)        | 4.5 (0.4)              | 4.4 (0.3)                 | <0.001               |
| AST (U/l)                  | 25 (15)          | 23 (10)                | 27 (18)                   | <0.001               |
| ALT (U/l)                  | 28 (27)          | 24 (15)                | 31 (31)                   | <0.001               |
| GGT (U/l)                  | 41 (46)          | 38 (48)                | 44 (44)                   | 0.062                |
| Total cholesterol (mmol/l) | 4.95 (1.04)      | 4.94 (0.92)            | 4.96 (1.10)               | 0.636                |
| Triglycerides (mmol/l)     | 1.66 (1.36)      | 1.42 (0.96)            | 1.79 (1.52)               | <0.001               |
| HDL-C (mmol/l)             | 1.35 (0.47)      | 1.39 (0.35)            | 1.34 (0.51)               | 0.009                |
| LDL-C (mmol/l)             | 2.93 (0.93)      | 3.00 (0.82)            | 2.89 (0.99)               | 0.005                |
| eGFR (ml/min/1.73 m$^2$)   | 93.6 (23.6)      | 96.2 (28.1)            | 92.3 (21.0)               | 0.006                |
| HOMA-IR                    | 2.7 (2.3)        | 1.9 (1.2)              | 3.2 (2.6)                 | <0.001               |
| HOMA-β (%)                 | 69.1 (52.4)      | 76.1 (49.4)            | 65.0 (53.8)               | <0.001               |

Figure 1. Estimating regression model analysis with unknown break-points.
doi:10.1371/journal.pone.0095729.g001
and 6.5% HbA1c, a well-known cut-off value for the diagnosis of diabetes [8,9], we adopted both 5.9% and 6.5% HbA1c as reference points for use in this study. In the ranges of non-diabetes, mean values of GA/HbA1c ratio (2.16 to 2.17) were similar. In the ranges of diabetes, however, the mean values of GA/HbA1c ratio ranged from 2.34 to 3.17. Similar to previous study [4], which included patients with T2D who were receiving medications, the mean GA/HbA1c ratio (2.48–3.13) increased as HbA1c increased.

Table 2. Means and selected percentiles of GA, FPG, HbA1c, HOMA-IR and HOMA-β levels in subjects with NGT according to the sex.

| Variables      | Mean (SD) | Percentile | 5th  | 25th  | 50th  | 75th  | 95th  |
|----------------|-----------|------------|------|-------|-------|-------|-------|
| GA (%)         |           |            |      |       |       |       |       |
| Total          | 11.5 (1.4)| 9.0        | 11.0 | 11.3  | 12.5  | 14.0  |
| Men            | 11.5 (1.2)| 10.0       | 11.0 | 11.1  | 12.1  | 13.5  |
| Women          | 11.6 (1.6)| 9.0        | 10.9 | 11.4  | 12.5  | 14.2  |
| FPG (mmol/l)   |           |            |      |       |       |       |       |
| Total          | 5.03 (0.37)| 4.27      | 4.83 | 5.11  | 5.33  | 5.49  |
| Men            | 5.04 (0.37)| 4.24      | 4.83 | 5.11  | 5.33  | 5.49  |
| Women          | 5.03 (0.37)| 4.25      | 4.83 | 5.11  | 5.33  | 5.49  |
| HbA1c (%)      |           |            |      |       |       |       |       |
| Total          | 5.4 (0.2) | 5.0        | 5.4  | 5.5   | 5.6   | 5.6   |
| Men            | 5.4 (0.2) | 5.0        | 5.4  | 5.5   | 5.6   | 5.6   |
| Women          | 5.4 (0.2) | 5.0        | 5.3  | 5.5   | 5.6   | 5.6   |
| HOMA-IR        |           |            |      |       |       |       |       |
| Total          | 1.4 (0.9) | 0.5        | 0.8  | 1.2   | 1.8   | 3.0   |
| Men            | 1.5 (1.1) | 0.4        | 0.8  | 1.2   | 1.9   | 4.3   |
| Women          | 1.4 (0.7) | 0.6        | 0.8  | 1.2   | 1.8   | 2.6   |
| HOMA-β (%)     |           |            |      |       |       |       |       |
| Total          | 85.3 (62.6)| 28.5      | 47.2 | 70.9  | 100.1 | 213.9 |
| Men            | 85.3 (59.6)| 21.1      | 48.6 | 70.7  | 99.5  | 224.9 |
| Women          | 85.4 (64.8)| 31.4      | 45.7 | 71.6  | 101.5 | 190.4 |

The number of men, and women tested were 107, and 155, respectively.
doi:10.1371/journal.pone.0095729.t002

Discussion

Current clinical guidelines for assessment of glycemic control recommend self-monitoring of blood glucose (SMBG) by patient and HbA1c as a part of hospital continuing care [8,9]. The latter is thought to reflect the average glycemia over a few months and has a strong predictive value for diabetes complications demonstrated in the large-scale studies such as the Diabetes Control and Complications Trial (DCCT) and U.K. Prospective Diabetes Study (UKPDS) [11–13]. However, notwithstanding the effects of erythrocyte turnover (hemolysis, blood loss) and hemoglobin

Figure 2. Correlation between HbA1c and GA (A), FPG and HbA1c (B), and FPG and GA (C).
doi:10.1371/journal.pone.0095729.g002
Table 3. Mean values of glycemic parameters according to HbA1c.

| HbA1c (%) | N (%) | HbA1c (%) | GA (%) | GA/A1c | FPG (mmol/l) |
|-----------|-------|-----------|--------|--------|--------------|
| HbA1c<5.9 | 736 (36.0) | 5.5 | 11.9 | 2.16 | 5.58 |
| 5.9≤HbA1c<6.5 | 575 (28.1) | 6.1 | 13.3 | 2.17 | 6.04 |
| 6.5≤HbA1c<7.5 | 370 (18.1) | 6.8 | 16.0 | 2.34 | 6.90 |
| 7.5≤HbA1c<8.5 | 143 (7.0) | 7.8 | 18.7 | 2.38 | 7.80 |
| 8.5≤HbA1c<9.5 | 71 (3.5) | 8.9 | 23.6 | 2.65 | 9.14 |
| 9.5≤HbA1c<10.5 | 49 (2.4) | 10.0 | 26.9 | 2.70 | 9.97 |
| 10.5≤HbA1c<11.5 | 41 (2.0) | 11.0 | 29.7 | 2.71 | 11.47 |
| 11.5≤HbA1c<12.5 | 29 (1.4) | 11.8 | 35.6 | 3.02 | 11.53 |
| HbA1c≥12.5 | 29 (1.4) | 13.6 | 43.3 | 3.17 | 15.25 |

Regarding the reference values for GA, it ranged between 11.9–15.8% (mean ±2 SD) in a healthy American population of both white and black patients without a known history of diabetes in North Carolina (n = 201 patients); this range was determined using the 75-g oral glucose tolerance test (OGTT) and demonstrated a significant racial difference [16]. In a study with a limited number of Italian patients (n = 32), the GA of the normal control group ranged between 11.7–16.9% (2.5–97.5th percentile) [17]. In a study conducted by the Japan Diabetes Society, the reference range for GA determined using 75-g OGTT in a selected Japanese reference population (n = 699 patients) was 12.3–16.9% (mean ±2 SD) [18]. In Chinese patients with NGT (n = 380), the 2.5–97.5th percentile was 10.8–17.1% GA [19]. On the other hand, the reference range (9.0–14.0%) GA corresponding to the 5–95th percentile in this population of Korean patients (n = 2043) did not exactly correspond to other Asian ethnicities, including Japanese and Chinese populations. This could be explained by the different FPG cutoff values that were used to define NGT (<110 mg/dL in Japanese population) [18] and the fact that 75-g OGTT was not used to assess our Korean population. In addition, we included patients with both FPG <5.55 mmol/l and HbA1c <5.7%. Similar to the racial differences noted in the American population, ethnic differences are debatable and require further investigations. Furthermore, there are no international standards for GA or any external quality assessment programs. Therefore, international standardization is clearly required for use in both clinical practice and research.

Table 3. Mean values of glycemic parameters according to HbA1c.

| HbA1c (%) | N (%) | HbA1c (%) | GA (%) | GA/A1c | FPG (mmol/l) |
|-----------|-------|-----------|--------|--------|--------------|
| HbA1c<5.9 | 736 (36.0) | 5.5 | 11.9 | 2.16 | 5.58 |
| 5.9≤HbA1c<6.5 | 575 (28.1) | 6.1 | 13.3 | 2.17 | 6.04 |
| 6.5≤HbA1c<7.5 | 370 (18.1) | 6.8 | 16.0 | 2.34 | 6.90 |
| 7.5≤HbA1c<8.5 | 143 (7.0) | 7.8 | 18.7 | 2.38 | 7.80 |
| 8.5≤HbA1c<9.5 | 71 (3.5) | 8.9 | 23.6 | 2.65 | 9.14 |
| 9.5≤HbA1c<10.5 | 49 (2.4) | 10.0 | 26.9 | 2.70 | 9.97 |
| 10.5≤HbA1c<11.5 | 41 (2.0) | 11.0 | 29.7 | 2.71 | 11.47 |
| 11.5≤HbA1c<12.5 | 29 (1.4) | 11.8 | 35.6 | 3.02 | 11.53 |
| HbA1c≥12.5 | 29 (1.4) | 13.6 | 43.3 | 3.17 | 15.25 |

To our previously reported equation (GA = -9.609+3.720 × HbA1c [%]) for newly diagnosed T2D patients corresponds well to the proposed conversion equation (GA = -8.01+3.66 × HbA1c [%]) [4].

There are a few important limitations to our study that warrant consideration, besides its retrospective nature. First, the lack of 2-
hour OGTT is a limitation because it may have resulted in the inclusion of patients with impaired glucose tolerance to the NGT group. Second, although we measured plasma GA at each hospital under the regulation of the US National Glycohemoglobin Standardization Program, it would be better if the GA measurements were performed by single central laboratory. Lastly, this study included only Korean patients, preventing generalization with other ethnic populations.

The present study suggests a reference range of 9.0–14.0% GA for Korean patients. Based on the continuous plots of GA and HbA1c in patients with normal and high glucose status, the significant glycemic turning points are 5.968% HbA1c and 12.2% GA. The proposed conversion equations below and above the turning point are GA (%) = 6.960 + 0.8963 × HbA1c (%) and GA (%) = −9.609 + 3.720 × HbA1c (%), respectively. Using the equation that we proposed, the differences between measured GA level and calculated GA level could be identified. These results should be helpful in future studies on investigating the clinical implication of GA as a glycemic index in specific patients with unexpected high GA levels over the HbA1c and the clinical implementation of diabetes management using GA.

Author Contributions
Conceived and designed the experiments: CHJ Y-CH JW B-WL. Performed the experiments: CHJ Y-CH KJK WSJ S-MJ SYR B-WL. Analyzed the data: CHJ Y-CH B-WL. Contributed reagents/materials/analysis tools: BSC C-YP JHK. Wrote the paper: CHJ Y-CH B-WL.

References
1. International Expert C (2009) International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 32: 1327–1334.
2. Kim KJ, Lee BW (2012) The roles of glycated albumin as intermediate glycation index and pathogenic protein. Diabetes Metab J 36: 90–107.
3. Kim D, Kim KJ, Huh JH, Lee BW, Kang ES, et al. (2012) The ratio of glycated albumin to glycated hemoglobin correlates with insulin secretory function. Clin Endocrinol (Oxf) 77: 679–684.
4. Lee EY, Lee BW, Kim D, Lee YH, Kim KJ, et al. (2011) Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetic patients. Acta Diabetol 48: 167–172.
5. Song SO, Kim KJ, Lee BW, Kang ES, Cha BS, et al. (2012) Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis 225: 450–453.
6. Koga M, Kasayama S (2010) Clinical impact of glycated albumin as another glycemic control marker. Endocr J 57: 751–762.
7. Tahara Y (2009) Analysis of the method for conversion between levels of HbA1c and glycated albumin by linear regression analysis using a measurement error model. Diabetes Res Clin Pract 84: 224–229.
8. American Diabetes A (2013) Standards of medical care in diabetes-2013. Diabetes Care 36 Suppl 1: S11–66.
9. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, et al. (2011) 2011 clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 35: 431–436.
10. Muggeo VM (2003) Estimating regression models with unknown break-points. Stat Med 22: 3055–3071.
11. The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.
12. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837–843.
13. Rhee SY, Chon S, Kwon MK, Park JI, B, Ahn KJ, et al. (2011) Prevalence of chronic complications in Korean patients with type 2 diabetes mellitus based on the Korean national diabetes program. Diabetes Metab J 35: 304–312.
14. Al-Ansary L, Farmer A, Hirst J, Roberts N, Glassiou P, et al. (2011) Point-of-care testing for HbA1c in the management of diabetes: a systematic review and metaanalysis. Clin Chem 57: 568–576.
15. Pu LJ, Lu L, Xu XW, Zhang RY, Zhang Q, et al. (2006) Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 5: 27.
16. Kohzuma T, Yamamoto T, Uematsu Y, Shihabri ZK, Freedman BI (2011) Basic performance of an enzymatic method for glycated albumin and reference range determination. J Diabetes Sci Technol 5: 1455–1462.
17. Parouli R, Ceriotti F, Galanello R, Battista Leonpi G, Panico A, et al. (2007) Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 40: 1398–1405.
18. Makoto T, Hideuchi M, Gen Y, Katsukihiko K, Izumi T, et al. (2006) Report of the Committee on Standardization of Laboratory Testing Related to Diabetes Mellitus of the Japan Diabetes Society: determination of reference intervals of hemoglobin A1c (IFCC) and glycoalbumin in the Japanese population. J Japan Diab Soc 49: 825–833.
19. Zhou J, Li H, Yang WY, Ran XW, Li Q, et al. (2009) A multi-center clinical study of the reference value of serum glycated albumin. Zhonghua Nei Ke Za Zhi 48: 469–472.
20. Garlick RL, Mazer JS (1983) The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem 258: 6142–6146.
21. Berg N, Fluckiger R (1986) Nonenzymatic glycosylation of albumin in vivo. Identification of multiple glycosylated sites. J Biol Chem 261: 13342–13345.
22. Roudeau P, Bouzou F. (2011) The glycation of albumin: structural and functional impacts. Biochimie 93: 645–658.